Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line Therapy in Metastatic Colorectal Cancer?

Por Nipp, Ryan D., Ryan, David P.
Publicado no Oncologist (2015)

Predicting a Response to FOLFIRINOX in Pancreatic Cancer

Por Nipp, Ryan D., Ryan, David P.
Publicado no J Natl Cancer Inst (2015)

Case 19-2010: A 35-Year-Old Man with Adenocarcinoma of the Cecum

Por Ryan, David P., Engelman, Jeffrey A., Ferrone, Cristina R., Sahani, Dushyant V., Lisovsky, Mikhail
Publicado em 2010

A blended knowledge translation initiative to improve colorectal cancer staging [ISRCTN56824239]

Por Wright, Frances C, Law, Calvin HL, Last, Linda D, Klar, Neil, Ryan, David P, Smith, Andrew J
Publicado em 2006

Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis

Por Goulart, Bernardo HL, Clark, Jeffrey W, Lauwers, Gregory Y, Ryan, David P, Grenon, Nina, Muzikansky, Alona, Zhu, Andrew X
Publicado em 2009

A Multicenter Retrospective Study on Clinical Characteristics, Treatment Patterns, and Outcome in Elderly Patients with Hepatocellular Carcinoma

Por Kozyreva, Olga N., Chi, Dorcas, Clark, Jeffrey W., Wang, Hejing, Theall, Kathy P., Ryan, David P., Zhu, Andrew X.
Publicado em 2011

Caring for One of Our Own

Por Schapira, Lidia, Blaszkowsky, Lawrence S., Cashavelly, Barbara J., Kim, Christina Y., Riley, John P., Wold, Mali C., Ryan, David P., Penson, Richard T.
Publicado em 2014

Quality of Life in Pancreatic Cancer: Analysis by Stage and Treatment

Por Crippa, Stefano, Domínguez, Ismael, Rodríguez, J. Ruben, Razo, Oswaldo, Thayer, Sarah P., Ryan, David P., Warshaw, Andrew L., Castillo, Carlos Fernández-del
Publicado em 2008

Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: Kinetics and potential biomarker value

Por Zhu, Andrew X., Duda, Dan G., Ancukiewicz, Marek, di Tomaso, Emmanuelle, Clark, Jeffrey W., Miksad, Rebecca, Fuchs, Charles S., Ryan, David P., Jain, Rakesh K.
Publicado em 2010

Phase I Study of Pasireotide (SOM 230) and Everolimus (RAD001) in Advanced Neuroendocrine Tumors

Por Chan, Jennifer A., Ryan, David P., Zhu, Andrew X., Abrams, Thomas A, Wolpin, Brian M, Malinowski, Paige, Regan, Eileen M, Fuchs, Charles S., Kulke, Matthew H.
Publicado no Endocr Relat Cancer (2012)

Long-term Results of Intraoperative Electron Beam Irradiation (IOERT) for Patients With Unresectable Pancreatic Cancer

Por Willett, Christopher G., Del Castillo, Carlos Fernandez, Shih, Helen A., Goldberg, Saveli, Biggs, Peter, Clark, Jeffrey W., Lauwers, Gregory, Ryan, David P., Zhu, Andrew X., Warshaw, Andrew L.
Publicado em 2005

O(6)-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors

Por Kulke, Matthew H., Hornick, Jason L., Frauenhoffer, Christine, Hooshmand, Susanne, Ryan, David P., Enzinger, Peter C., Meyerhardt, Jeffrey A., Clark, Jeffrey W., Stuart, Keith, Fuchs, Charles S., Redston, Mark S.
Publicado em 2009

Phase II Study of Everolimus in Patients With Metastatic Colorectal Adenocarcinoma Previously Treated With Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regim...

Por Ng, Kimmie, Tabernero, Josep, Hwang, Jimmy, Bajetta, Emilio, Sharma, Sunil, Del Prete, Salvatore A., Arrowsmith, Edward R., Ryan, David P., Sedova, Michaela, Jin, Jin, Malek, Kamel, Fuchs, Charles S.
Publicado em 2013

A Prospective, Phase I/II Study of Everolimus and Temozolomide in Patients with Advanced Pancreatic Neuroendocrine Tumor

Por Chan, Jennifer A., Blaszkowsky, Lawrence, Stuart, Keith, Zhu, Andrew X., Allen, Jill, Wadlow, Raymond, Ryan, David P., Meyerhardt, Jeffrey, Gonzalez, Marielle, Regan, Eileen, Zheng, Hui, Kulke, Matthew H.
Publicado no Cancer (2013)

Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer

Por Wolpin, Brian M., Hezel, Aram F., Abrams, Thomas, Blaszkowsky, Lawrence S., Meyerhardt, Jeffrey A., Chan, Jennifer A., Enzinger, Peter C., Allen, Brittany, Clark, Jeffrey W., Ryan, David P., Fuchs, Charles S.
Publicado em 2009

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers

Por Ebi, Hiromichi, Corcoran, Ryan B., Singh, Anurag, Chen, Zhao, Song, Youngchul, Lifshits, Eugene, Ryan, David P., Meyerhardt, Jeffrey A., Benes, Cyril, Settleman, Jeffrey, Wong, Kwok-Kin, Cantley, Lewis C., Engelman, Jeffrey A.
Publicado em 2011

A Phase 2 Study of Oral MKC-1 in Patients with Unresectable or Metastatic Pancreatic Cancer

Por Faris, Jason E., Arnott, Jamie, Zheng, Hui, Ryan, David P., Abrams, Thomas A., Blaszkowsky, Lawrence S., Clark, Jeffrey W., Enzinger, Peter C., Hezel, Aram F., Ng, Kimmie, Wolpin, Brian M., Kwak, Eunice L.
Publicado em 2011

Molecular heterogeneity and receptor co-amplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer

Por Kwak, Eunice L., Ahronian, Leanne G., Siravegna, Giulia, Mussolin, Benedetta, Godfrey, Jason T., Clark, Jeffrey W., Blaszkowsky, Lawrence S., Ryan, David P., Lennerz, Jochen K., Iafrate, A. John, Bardelli, Alberto, Hong, Theodore S., Corcoran, Ryan B.
Publicado no Cancer Discov (2015)

Intraductal Papillary Mucinous Adenocarcinoma of the Pancreas: Clinical Outcomes, Prognostic Factors, and the Role of Adjuvant Therapy

Por Alexander, Brian M., Fernandez-del Castillo, Carlos, Ryan, David P., Kachnic, Lisa A., Hezel, Aram F., Niemierko, Andrzej, Willett, Christopher G., Kozak, Kevin R., Blaszkowsky, Lawrence S., Clark, Jeffrey W., Warshaw, Andrew L., Hong, Theodore S.
Publicado em 2011

Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab

Por Wadlow, Raymond C., Hezel, Aram F., Abrams, Thomas A., Blaszkowsky, Lawrence S., Fuchs, Charles S., Kulke, Matthew H., Kwak, Eunice L., Meyerhardt, Jeffrey A., Ryan, David P., Szymonifka, Jackie, Wolpin, Brian M., Zhu, Andrew X., Clark, Jeffrey W.
Publicado em 2012